Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $289.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lifted by Wells Fargo & Company from $264.00 to $289.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

ASND has been the topic of several other reports. Bank of America upped their price objective on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a buy rating in a research report on Wednesday, September 4th. Jefferies Financial Group increased their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research report on Tuesday, August 13th. Stifel Nicolaus assumed coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective for the company. StockNews.com upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Thursday, September 5th. Finally, The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a buy rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $153.43 on Tuesday. The firm’s 50 day moving average price is $132.94 and its 200-day moving average price is $136.52. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The company has a market cap of $8.93 billion, a PE ratio of -15.49 and a beta of 0.63.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $36,000. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares in the last quarter. GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the period. Finally, Barometer Capital Management Inc. purchased a new stake in Ascendis Pharma A/S in the fourth quarter worth about $126,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.